Stock Report: PROLOR Biotech Inc. (PBTH) Report Updated: May 20, 2013 | Print This Page

PROLOR Biotech, Inc., a development stage biopharmaceutical company, engages in the development of proprietary versions of already-approved therapeutic proteins. Its technology, Carboxyl Terminal Peptide technology could be attached to an array of existing therapeutic proteins, stabilizing the therapeutic protein in the bloodstream and extending its life span without additional toxicity or loss of desired biological activity. The company’s products under development include Human Growth Hormone for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; and Factor IX to Hemophilia B patients for blood clotting under the BeneFIX brand name. Its products under development also comprise Anti-Obesity Peptide Oxyntomodulin; Factor VIIa; Interferon β and Erythropoietin; and Atherosclerosis and rheumatoid arthritis long-acting therapies. The company was formerly known as Modigene Inc. and changed its name to PROLOR Biotech, Inc. in June 2009. PROLOR Biotech, Inc. is based in Nes Ziona, Israel.